Citi Downgrades Clovis, Rates It As High Risk

By: via Benzinga
Citi analyst Yaron Werber downgraded Clovis Oncology (NASDAQ: CLVS) to Neutral/High Risk and issued a new price target of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.